Literature DB >> 10975380

P27 in cell cycle control and cancer.

M B Møller1.   

Abstract

In order to survive, cells need tight control of cell cycle progression. The control mechanisms are often lost in human cancer cells. The cell cycle is driven forward by cyclin-dependent kinases (CDKs). The CDK inhibitors (CKIs) are important regulators of the CDKs. As the name implies, CKIs were initially shown to negatively regulate CDK activity. However, recent data indicates that the members of the Kip/Cip family of CKIs, including p27, exert both positive and negative regulation of CDK activity at the G1/S phase transition. Mutations of Kip/Cip genes are rare, but p27 knockout mice are tumor prone when challenged with carcinogenic stimuli. Numerous studies of various human non-hematological tumors have identified low expression of p27 as a predictor of poor prognosis. In non-Hodgkin's lymphoma (NHL), we and others have also shown the independent prognostic value of p27 expression. In distinct NHL entities however, shortened survival seems to correlate with high expression of p27. For definitive assessment of the role played by p27 in lymphomagenesis, and the prognostic value of p27 in these tumors, further studies of distinct NHL entities are needed. This review addresses the function of p27 and the other Kip/Cip proteins in G1/S phase transition and their possible role in tumorigenesis with emphasis on p27 and NHL.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10975380     DOI: 10.3109/10428190009053535

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  24 in total

Review 1.  Landscape of Pin1 in the cell cycle.

Authors:  Cheng-Han Lin; Hao-Yi Li; Yu-Cheng Lee; Marcus J Calkins; Kuen-Haur Lee; Chia-Ning Yang; Pei-Jung Lu
Journal:  Exp Biol Med (Maywood)       Date:  2015-02-07

2.  CCN5/WISP-2 promotes growth arrest of triple-negative breast cancer cells through accumulation and trafficking of p27(Kip1) via Skp2 and FOXO3a regulation.

Authors:  I Haque; S Banerjee; A De; G Maity; S Sarkar; M Majumdar; S S Jha; D McGragor; S K Banerjee
Journal:  Oncogene       Date:  2014-08-18       Impact factor: 9.867

3.  Contribution of Cyclin-dependent Kinase Inhibitor 1B Genotypes to Childhood Leukemia Risk.

Authors:  Jen-Sheng Pei; Wen-Shin Chang; Pei-Chen Hsu; Chao-Chun Chen; Ya-Chen Yang; Shih-Wei Hsu; Yuan-Nian Hsu; Yun-Chi Wang; Chung-Hsing Wang; Chia-Wen Tsai; DA-Tian Bau
Journal:  In Vivo       Date:  2022 Jul-Aug       Impact factor: 2.406

4.  Crude extract of Desmodium gangeticum process anticancer activity via arresting cell cycle in G1 and modulating cell cycle-related protein expression in A549 human lung carcinoma cells.

Authors:  Yuh-Fung Chen; Yi-Hsien Lu; Huei-Yann Tsai
Journal:  Biomedicine (Taipei)       Date:  2022-06-01

Review 5.  ING proteins as potential anticancer drug targets.

Authors:  M Unoki; K Kumamoto; C C Harris
Journal:  Curr Drug Targets       Date:  2009-05       Impact factor: 3.465

6.  Expression of geminin as a marker of cell proliferation in normal tissues and malignancies.

Authors:  James A Wohlschlegel; Jeffery L Kutok; Andrew P Weng; Anindya Dutta
Journal:  Am J Pathol       Date:  2002-07       Impact factor: 4.307

7.  A novel treatment strategy in hepatocellular carcinoma by down-regulation of histone deacetylase 1 expression using a shRNA lentiviral system.

Authors:  Huancheng Zhou; Jie Wang; Guangfu Peng; Yue Song; Caiyun Zhang
Journal:  Int J Clin Exp Med       Date:  2015-10-15

8.  Antitumor effects of galectin-3 inhibition in human renal carcinoma cells.

Authors:  Yangyang Xu; Changfu Li; Jiahang Sun; Jingshu Li; Xin Gu; Wanhai Xu
Journal:  Exp Biol Med (Maywood)       Date:  2016-02-03

9.  Resident hepatocyte fibroblast growth factor receptor 4 limits hepatocarcinogenesis.

Authors:  Xinqiang Huang; Chaofeng Yang; Chengliu Jin; Yongde Luo; Fen Wang; Wallace L McKeehan
Journal:  Mol Carcinog       Date:  2009-06       Impact factor: 4.784

10.  Role of TGF-β signaling in uterine carcinosarcoma.

Authors:  Shailendra Kumar Dhar Dwivedi; Scott D McMeekin; Katrina Slaughter; Resham Bhattacharya
Journal:  Oncotarget       Date:  2015-06-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.